Compare Crispr Therapeutics AG (CRSP) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Nokia Corp — how do they compare? Crispr Therapeutics AG trades at $53.87 (market cap $5.23B), while Nokia Corp trades at $10.39 (market cap $53.00B). The key difference: Nokia Corp is far larger — about 10.1× Crispr Therapeutics AG's market cap, and Nokia Corp pays a 1.73% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | NOK | |
|---|---|---|
Market Cap | $5.23B | $53.00B |
Sector | Health | Technology |
52-Week High | $76.78 | $16.83 |
52-Week Low | $44.34 | $4.13 |
Enterprise Value | $3.65B | $50.95B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Nokia (NOK) trades at $10.375, up 13.76% today, reflecting strong momentum amid AI infrastructure demand. The stock shows mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, Q2 2026 earnings beat profit estimates, driven by AI and cloud growth, though revenue missed. Analyst sentiment is bullish with 60% buy ratings, while cash flow trends indicate volatility with a net outflow of $1.16B in 2025.
The outlook is cautiously optimistic, with AI-driven demand offsetting telecom challenges. Key opportunities include expanding AI networking and cloud infrastructure, but risks involve uneven telecom spending and competitive pressures. Investors should weigh strong analyst support against cash flow instability and margin pressures for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
